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Growing evidence suggests that active vitamin D slows the
progression of chronic kidney diseases. Here we compared
the individual renal protective efficacy of paricalcitol and
trandolapril (an angiotensin-converting enzyme inhibitor)
in obstructive nephropathy, and examined any potential
additive effects of their combination on attenuating renal
fibrosis and inflammation. Mice underwent unilateral ureteral
obstruction and were treated individually with paricalcitol
or trandolapril or their combination. Compared to
vehicle-treated controls, monotherapy with paricalcitol or
trandolapril inhibited the expression and accumulation of
fibronectin and type I and type III collagen, suppressed a-
smooth muscle actin, vimentin, and Snail1 expression, and
reduced total collagen content in the obstructed kidney.
Combination therapy led to a more profound inhibition of all
parameters. Monotherapy also suppressed renal RANTES
(regulated on activation, normal T cell expressed and
secreted) and tumor necrosis factor (TNF)-a expression and
inhibited renal infiltration of T cells and macrophages,
whereas the combination had additive effects. Renin
expression was induced in the fibrotic kidney and was
augmented by trandolapril. Paricalcitol blocked renin
induction in the absence or presence of trandolapril. Our
study indicates that paricalcitol has renal protective effects,
comparable to that of trandolapril, in reducing interstitial
fibrosis and inflammation. Combination therapy had additive
efficacy in retarding renal scar formation during obstructive
nephropathy.
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Chronic kidney disease (CKD) is a progressive, devastating
illness that eventually results in end-stage renal failure, and
the number of patients is increasing at a rate of 6–8%
annually worldwide.1–4 Once CKD progresses to end-stage
renal failure, mortality of patients on dialysis approaches
20% per year. Notably, most patients with CKD are identified
well before they reach end-stage renal failure; however, no
currently available treatment is effective in completely halting
the progressive loss of renal function. These data underscore
the importance and urgency of developing effective thera-
peutic strategies for the treatment of CKD.
In the past decade, agents that target the renin–angiotensin
system (RAS), including angiotensin-converting enzyme
inhibitor and angiotensin II receptor blockers, have been
introduced successfully into renal medicine and are increas-
ingly becoming the standard treatment regimen for CKD
patients.5,6 The actions of these agents result in either block-
ing the generation or hampering the function of angiotensin
II, a multifunctional peptide that is upregulated in injured
kidney, and elicits its pathogenic activities through diverse
mechanisms. However, one major drawback of RAS inhibi-
tion in patients is the compensatory increase in renin,7 an
enzyme that promotes renal injury not only by stimulating
angiotensin II production but also by eliciting cellular
activities through renin/prorenin receptor.8,9 In addition,
the driving force behind CKD progression could be
multifactorial.10,11 As a result, targeting angiotensin II alone
may at best only slow, but not block or reverse, the
progression of kidney functional impairment.5,6 In this
context, a combination therapy with different classes of
agents that target independent pathogenic pathways may be a
rational strategy for designing future therapy for human
CKD in clinical settings.
Several clinical studies have shown that deficiency of
vitamin D and its active metabolites is a common feature that
occurs early in the pathogenesis of CKD.12,13 Interestingly,
supplementation of vitamin D receptor (VDR) activators in
CKD patients reduces proteinuria and all-cause mortality,
which is independent of serum parathyroid hormone,
phosphorus, and calcium levels.14–19 In experimental models
of CKD, VDR activators have been shown to reduce
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proteinuria, inhibit renal inflammation, and attenuate renal
interstitial fibrosis in remnant kidney, as well as in diabetic
and obstructive nephropathy.20–24 The beneficial effects of
vitamin D may be attributable to its anti-inflammatory,
prodifferentiation properties, as well as to its inhibition of
renin expression.20,24–26 We have recently shown that
paricalcitol (19-nor-1,25-hydroxy-vitamin D2), a selective,
new generation VDR activator that retains similar, if not
better, vitamin D biological activity but shows less undesir-
able effects and better tolerance,27–30 attenuates renal
interstitial fibrosis by blocking tubular epithelial-to-mesench-
ymal transition (EMT).20 Furthermore, paricalcitol sup-
presses proinflammatory chemokine expression and inhibits
renal inflammation by targeting NF-kB signaling.25 These
results suggest that selective VDR activators could be an
arsenal in the fight against CKD.
In this study, we sought to directly compare the renal
protective efficacy of paricalcitol and trandolapril, an
angiotensin-converting enzyme inhibitor, in a mouse model
of obstructive nephropathy, and to assess any potential
additive effects of the combination therapy on attenuating
renal interstitial fibrosis and inflammation.
RESULTS
Combination therapy inhibits renal interstitial matrix gene
expression
We first compared the effects of paricalcitol and trandolapril
on the expression of several interstitial matrix genes in the
fibrotic kidney induced by unilateral ureteral obstruction
(UUO). As shown in Figure 1, compared with sham controls,
obstructive injury caused a 17.8-, 5.9-, and 6.9-fold induction
of fibronectin, type I, and type III collagen mRNA
abundances, respectively. Monotherapy with paricalcitol or
trandolapril alone substantially reduced the mRNA expres-
sion of these interstitial matrix genes. Interestingly, parical-
citol seemed to be more potent than trandolapril in
suppressing fibronectin and type I collagen mRNA expression
(Figure 1), although it inhibited type III collagen expression
in a similar magnitude as trandolapril. Combination of both
resulted in a further additive suppression of the expression of
these matrix genes, producing more profound effects than
paricalcitol or trandolapril treatment alone (Figure 1a–c).
We further examined the interstitial matrix deposition and
accumulation in fibrotic kidney after various treatments. As
shown in Figure 1d, compared with sham-operated kidney, a
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Figure 1 |Mono- or combination therapy with paricalcitol and trandolapril suppresses renal interstitial matrix expression.
(a) Representative reverse transcriptase (RT)-PCR results showed the mRNA expression of fibronectin, type I, and type III collagen in
obstructed kidney 7 days after unilateral ureteral obstruction (UUO), following various treatments as indicated. Numbers 1, 2, and 3 denote
each individual animal. Graphic presentation of fibronectin (b) and type I and III collagen (c) mRNA levels of interstitial matrix components
in different groups. Relative mRNA levels were determined by densitometric analysis, calculated after normalization with
b-actin, and expressed as fold induction over sham controls (value¼ 1.0). Data are expressed as mean±s.e.m. (n¼ 5). *Po0.01 versus
vehicle controls; wPo0.05 versus paricalcitol or trandolapril alone. (d) Representative micrographs show renal fibronectin and type I collagen
deposition and accumulation in obstructed kidney 7 days after UUO, following various treatments as indicated. Bar¼ 50mm. Col, collagen;
Fn, fibronectin; P, paricalcitol; T, trandolapril; V, vehicle.
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dramatic deposition and accumulation of fibronectin and
type I collagen was found in obstructed kidney 7 days after
UUO, as shown by indirect immunofluorescence staining.
Consistent with mRNA data, monotherapy with paricalcitol
or trandolapril alone attenuated both fibronectin and type I
collagen accumulation, and a combination of both resulted in
a further additive reduction of these interstitial matrix
components (Figure 1d).
Combination therapy ameliorates renal myofibroblast
activation
We next investigated the effects of mono- or combination
therapy with paricalcitol and trandolapril on the renal
expression of a-smooth muscle actin (a-SMA), the molecular
signature for myofibroblast activation. As shown in Figure 2a
and b, either paricalcitol or trandolapril treatment alone
inhibited a-SMA mRNA expression in obstructed kidney,
when compared with vehicle controls. The effects of pari-
calcitol and trandolapril were comparable. A combination of
both showed a tendency of additive inhibition of a-SMA
mRNA expression, although the difference did not reach
statistical significance. However, western blot analyses of
whole-kidney homogenates clearly showed an additive effect
of paricalcitol and trandolapril on the inhibition of
a-SMA protein expression (Figure 2c and d).
Inhibition of Snail1 and vimentin expression
Snail1 is a transcription factor that is implicated in mediating
tubular EMT and renal fibrosis.31,32 As shown in Figure 3,
Snail1 mRNA was induced in the obstructed kidney, and
paricalcitol was able to suppress Snail1 expression, consistent
with our previous report.20 Interestingly, trandolapril also
significantly inhibited renal Snail1 expression after obstruc-
tive injury. Furthermore, a combination therapy with
paricalcitol and trandolapril showed an additive effect on
blocking Snail1 induction (Figure 3a and b).
We further examined the expression of vimentin, a
mesenchymal marker, in obstructed kidney after various
treatments. As shown in Figure 3c, obstructive injury caused
tubular dilatation and induced de novo expression of
vimentin 7 days after ureteral ligation. Of interest, vimentin
was predominantly localized in renal tubules after injury
(Figure 3c, arrows), consistent with the notion of tubular
EMT in this model. Either paricalcitol or trandolapril
substantially inhibited renal vimentin expression, and a
combination of both resulted in an almost complete
suppression of its expression (Figure 3c).
Combination therapy preserves TBM integrity and reduces
renal total collagen content
We also examined the expression of type IV collagen, a major
component of the tubular basement membrane (TBM) in
obstructed kidney. As shown in Figure 4a, type IV collagen
staining outlined the TBM in sham-operated kidney.
Obstructive injury clearly caused a disruption of TBM
integrity, with a broken staining pattern for type IV collagen
(Figure 4a, arrowheads). The interstitial space was expanded
in the obstructed kidney, with aggregates of type IV collagen
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Figure 2 |Mono- or combination therapy with paricalcitol and trandolapril inhibits renal a-smooth muscle actin (a-SMA) mRNA and
protein expression in obstructive nephropathy. (a and b) Reverse transcriptase (RT)-PCR showed mRNA levels of a-SMA in obstructed
kidneys after various treatments as indicated. Representative RT-PCR results (a) and quantitative determination of a-SMA mRNA abundances
(b) are presented. Numbers 1, 2, and 3 denote each individual animal. (c and d) Western blot analyses showed the a-SMA protein expression
in different groups. Representative western blots (c) and quantitative data (d) are presented. Numbers 1 and 2 denote each individual
animal. Data in b and d are expressed as mean±s.e.m. (n¼ 5). *Po0.01 versus vehicle controls. wPo0.05 versus paricalcitol or trandolapril
alone. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; P, paricalcitol; T, trandolapril; UUO, unilateral ureteral obstruction.
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staining (Figure 4a, arrows). A semiquantitative determina-
tion of the interstitial space among different groups is
presented in Figure 4b.
We also compared the effects of paricalcitol and
trandolapril on renal total collagen content after obstructive
injury. The kidney tissue total collagen content was estimated
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Figure 3 |Mono- or combination therapy with paricalcitol and trandolapril inhibits renal Snail1 and tubular vimentin expression.
(a) Representative reverse transcriptase (RT)-PCR showed Snail1 mRNA expression in obstructed kidney after various treatments. Numbers 1,
2, and 3 denote each individual animal. (b) Graphic presentation of Snail1 mRNA levels in different groups. Relative mRNA levels were
determined by densitometric analysis, calculated after normalization with b-actin, and expressed as fold induction over sham controls
(value¼ 1.0). Data are expressed as mean±s.e.m. (n¼ 5). *Po0.01 versus that of vehicle controls. wPo0.05 versus that of paricalcitol or
trandolapril alone. (c) Immunohistochemical staining shows de novo vimentin expression in the obstructed kidney 7 days after unilateral
ureteral obstruction (UUO), following various treatments as indicated. Arrows denote vimentin-positive tubular cells. Bar¼ 50mm.
P, paricalcitol; T, trandolapril.
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Figure 4 |Mono- or combination therapy with paricalcitol and trandolapril preserves tubular basement membrane (TBM) integrity
and reduces renal total collagen content. (a) Representative micrographs show renal type IV collagen staining in the obstructed kidney
7 days after unilateral ureteral obstruction (UUO), following various treatments as indicated. Arrowheads indicate a disrupted TBM.
Arrows denote the interstitial space with aggregates of type IV collagen staining. Bar¼ 50 mm. (b) Graphic presentation of the interstitial
volume index in different groups. Interstitial volume index was determined and expressed as the percentage of interstitial space in a
given field. (c) Renal total collagen content was estimated by measuring hydroxyproline levels in obstructed kidney 7 days after UUO,
following various treatments as indicated. Hydroxyproline levels were expressed as mg/mg of dry kidney weight. Data are expressed as
mean±s.e.m. (n¼ 5). *Po0.01 versus vehicle controls; wPo0.05 versus paricalcitol or trandolapril alone. P, paricalcitol; T, trandolapril.
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by measuring hydroxyproline levels after various treatments.
As shown in Figure 4c, 7 days after UUO, the renal total
collagen content as reflected by the hydroxyproline level
dramatically increased, compared with that in sham con-
trols. Monotherapy with either paricalcitol or trandolapril
significantly reduced the renal total collagen content, and a
combination of both resulted in a further reduction of
collagen deposited in fibrotic kidney (Figure 4c).
Inhibition of renal RANTES and TNF-a expression
As interstitial inflammation is a major feature of obstructive
injury,33 we next investigated the effects of mono- or com-
bination therapy with paricalcitol and trandolapril on proin-
flammatory cytokines expression. As shown in Figure 5, a
marked induction of proinflammatory cytokines RANTES
(regulated on activation, normal T cell expressed and secreted)
and tumor necrosis factor-a (TNF-a) expression was obser-
ved in obstructed kidney, when compared with that in sham
controls. Treatment with paricalcitol or trandolapril alone
significantly inhibited RANTES and TNF-a expression, and
combination of both led to a further inhibition of these
cytokines (Figure 5).
Combination therapy reduces the renal infiltration of
inflammatory T cells and macrophages
We further examined the effects of mono- or combination
therapy with paricalcitol and trandolapril on renal inflam-
matory cell infiltration. As shown in Figure 6a and b, ureteral
obstruction induced substantial infiltration of F4/80-positive
monocytes/macrophages into the renal interstitium, com-
pared with that in sham controls. Paricalcitol or trandolapril
treatment alone inhibited macrophage infiltration, and a
combination of both showed a further suppression of the
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Figure 5 |Mono- or combination therapy with paricalcitol
and trandolapril inhibits renal proinflammatory cytokine
expression. (a) Representative reverse transcriptase (RT)-PCR
results showed tumor necrosis factor-a (TNF-a) and RANTES
(regulated on activation, normal T cell expressed and
secreted) mRNA expression in obstructed kidney after various
treatments. Numbers 1, 2, and 3 denote each individual
animal. (b) Graphic presentation of TNF-a and RANTES
mRNA levels in different groups. Relative mRNA levels were
determined after normalization with b-actin, and expressed
as fold induction over sham controls (value¼ 1.0). Data are
expressed as mean±s.e.m. (n¼ 5). *Po0.01 versus vehicle
controls. wPo0.05 versus paricalcitol or trandolapril alone.
P, paricalcitol; T, trandolapril; UUO, unilateral ureteral
obstruction.
F4
/8
0+
 c
el
l in
filt
ra
tio
n
(%
 of
 po
sit
ive
 g
rid
) 25
20
15
10
5
0
Sham V P T P+T
UUO
*
*
*
†
Figure 6 |Mono- or combination therapy with paricalcitol and trandolapril inhibits renal infiltration of inflammatory monocytes/
macrophages. (a–e) Immunohistochemical staining showed an increased infiltration of F4/80þ myeloid cells including macrophages
and dendritic cells in obstructed kidney 7 days after unilateral ureteral obstruction (UUO) (b), compared with sham control (a).
Monotherapy with either paricalcitol (c) or trandolapril (d), or in combination (e), inhibits renal infiltration of inflammatory
monocytes/macrophages. Bar¼ 50 mm. (f) Graphic presentation of quantitative data. Data are means±s.e.m. of five animals per
group (n¼ 5). *Po0.01 versus vehicle controls. wPo0.05 versus paricalcitol or trandolapril alone. P, paricalcitol; T, trandolapril;
V, vehicle.
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renal infiltration of these inflammatory cells (Figure 6).
Similarly, monotherapy with either paricalcitol or trandola-
pril inhibited CD3-positive T-cell infiltration, and
combination therapy with both showed an additive effect
on blocking T-cell infiltration after obstructive injury
(Figure 7).
Paricalcitol blocks compensatory renin induction
To explore the mechanism underlying the efficacy of
combination therapy, we investigated the renin expression
in the kidneys after different treatments. As shown in
Figure 8a and b, obstructive injury induced renal renin
mRNA expression. However, paricalcitol and trandolapril
showed an opposite effect on renin expression in obstructed
kidney. Although paricalcitol abolished renin induction in
obstructed kidney, trandolapril significantly augmented renin
expression after injury, suggesting that RAS inhibition leads
to a compensatory renin expression. Combination therapy
with both effectively blocked the compensatory renin
expression induced by trandolapril. Virtually same results
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Figure 7 |Mono- or combination therapy with paricalcitol and trandolapril inhibits renal inflammatory T-cell infiltration. (a–e)
Immunohistochemical staining showed an increased infiltration of CD3þ T cells in obstructed kidney 7 days after unilateral ureteral
obstruction (UUO) (b), compared with sham control (a). Monotherapy with paricalcitol (c) or trandolapril (d), or in combination (e), inhibits
renal infiltration of inflammatory T cells. Bar¼ 50mm. (f) Graphic presentation of quantitative data. Data are means±s.e.m. of five animals
per group (n¼ 5). *Po0.01 versus vehicle controls. wPo0.05 versus paricalcitol or trandolapril alone. P, paricalcitol; T, trandolapril; V, vehicle.
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Figure 8 |Paricalcitol abolishes renin induction by trandolapril in fibrotic kidney. (a) Reverse transcriptase (RT)-PCR results showed
renin mRNA expression in obstructed kidney after various treatments. Numbers 1, 2, and 3 denote each individual animal in a given group.
(b) Graphic presentation of renin mRNA levels in different groups. Relative mRNA levels were determined after normalization with b-actin,
and expressed as fold induction over sham controls (value¼ 1.0). Data are expressed as mean±s.e.m (n¼ 5). *Po0.01 versus sham.
wPo0.05 versus vehicle group. #Po0.05 versus trandolapril alone. (c) Representative micrographs showed renin protein expression and
localization by immunohistochemical staining in different groups as indicated. Arrow indicates renin-positive cells. Bar¼ 50 mm.
P, paricalcitol; T, trandolapril; UUO, unilateral uretal obstruction.
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were obtained by immunohistochemical staining for renin
protein (Figure 8c). In normal mouse kidney, renin-positive
cells were found in the juxtaglomerular apparatus and
occasionally in distal tubules. However, obstructive injury
induced de novo renin expression in proximal tubules, which
was markedly augmented by trandolapril (Figure 8c). It is
interesting that renin expression in renal tubules showed
discernible heterogeneity, with various levels of renin protein
in different cells even within the same tubule (Figure 8c,
arrow). Similarly, paricalcitol apparently abolished the
compensatory renin protein induction by trandolapril in
renal tubules (Figure 8c).
DISCUSSION
The results presented in this study indicate that paricalcitol,
a low-calcemic vitamin D analog, shows significant renal
protection in a magnitude that is comparable with tran-
dolapril, an angiotensin-converting enzyme inhibitor that
is widely used in the treatment of renal and cardiovas-
cular diseases. This side-by-side comparison of thera-
peutic efficacy has established that VDR activator seems
as equally effective as standard RAS inhibitor in suppres-
sing matrix gene expression, interstitial inflammation, and
total collagen accumulation in obstructive nephropathy.
Furthermore, a combination of both leads to additive
efficacy in ameliorating renal inflammation and fibrotic
lesions, suggesting that multitarget therapy using different
classes of drugs could be a rational strategy in designing a
future treatment regimen for human CKD in a clinical
setting.
The VDR activators are approved to be used clinically for
the treatment of secondary hyperparathyroidism in patients
with chronic renal insufficiency.27 The suppressive effect of
VDR activators on the parathyroid hormone is primarily
mediated by its inhibitory effects on the parathyroid gland,
and its regulation of calcium and phosphorus absorption in
the intestine and mobilization in the bone.34,35 Usage of
nonselective VDR activators, such as calcitriol (1,25-dihy-
droxyvitamin D3), is often associated with dose-limiting
hypercalcemia and hyperphosphatemia. However, selective
VDR activators such as paricalcitol have minimal
adverse effects on calcium absorption in the intestine, and
thereby show a better tolerance profile.29,30 We have
previously shown that paricalcitol at a high dose (0.3 mg/kg
body weight (BW)) does not cause an increase in the serum
calcium level or induce calcium deposition.20 Whether
long-term treatment of paricalcitol causes any adverse effects
in other organs awaits further investigation, as a previous
study shows that administration of paricalcitol is associated
with perivascular fibrosis and an increased cardiac connective
tissue growth factor expression in remnant kidney rats.36
Interestingly, treatment with paricalcitol or with other VDR
activators has shown survival benefit in dialysis patients,
which is independent of serum parathyroid hormone,
phosphorus, and calcium levels,14–19 suggesting that some
‘non-classical’ actions of VDR activators are responsible for
its beneficial effects in slowing down the progression of renal
insufficiency.
The reno-protective effects of paricalcitol are primarily
linked to its properties as a prodifferentiation and
anti-inflammatory agent. By virtue of its ability to regulate
gene expression as a transcription factor ligand, the VDR
activator affects many physiological processes, such as cell
differentiation, immune response, and blood pressure
regulation, besides calcium–phosphate homeostasis. The
ability of paricalcitol to inhibit myofibroblast activation
and the expression of interstitial matrix genes, including
fibronectin, collage I, and collagen III, is consistent with its
role in preserving the tubular epithelial cell phenotype, as a
significant proportion of renal fibroblasts is derived from
renal tubules through EMT in this model.37,38 Consistent
with this view, paricalcitol also significantly represses Snail1,
a key EMT-regulatory transcription factor that induces
tubular EMT and renal fibrosis in vitro and in vivo,20,32 and
inhibits the tubular expression of vimentin and preserves
TBM integrity (Figures 3 and 4). In addition, paricalcitol also
inhibits proinflammatory cytokines RANTES and TNF-a
expression, which leads to the inhibition of renal infiltration
of inflammatory cells including macrophages and T cells
(Figures 5–7). The anti-inflammatory effects of paricalcitol
are mainly mediated by its VDR-mediated sequestration of
NF-kB signaling, as shown previously.25
Many components of RAS, including angiotensinogen,
renin, and angiotensin II receptors, are upregulated in
chronic fibrotic kidney.22 Angiotensin II, the principal
mediator of RAS, promotes the progression of kidney injury
in multiple ways. Besides elevating systemic and intraglo-
merular capillary pressure, angiotensin II can exert fibrogenic
effects by directly acting on various kidney cells through
induction of TGF-b1, promotion of inflammatory cell
infiltration, and stimulation of extracellular matrix expres-
sion. Not surprisingly, administration of trandolapril, an
angiotensin-converting enzyme inhibitor that blocks angio-
tensin II generation, inhibits matrix production, and
suppresses proinflammatory cytokine expression and reduces
renal inflammation. It is noteworthy that trandolapril also
significantly suppresses Snail1 expression after obstructive
injury (Figure 3), implying its role in blocking tubular EMT
in this model. This notion is substantiated by recent
observations in which angiotensin II can activate Smad
signaling in a TGF-b1-independent manner, and thereby
induce tubular EMT and renal fibrosis.39,40
This study illustrates a synergy between the RAS inhibitor
and VDR activator in reducing renal fibrosis and inflamma-
tion, which is supported by recent studies using different
models of CKD.23,24 The mechanistic basis for such synergy is
not completely understood at this stage, but it could be
related to the renin inhibition by VDR activators. Obstructive
injury causes renin induction in tubular epithelial cells, which
is blocked by paricalcitol (Figure 8), consistent with a
previous observation that vitamin D analog is a negative
regulator of renin expression.26 It is well known that RAS
1254 Kidney International (2009) 76, 1248–1257
or ig ina l a r t i c l e X Tan et al.: Combined therapy with paricalcitol and ACEI
inhibitors in patients often induce a compensatory increase
in plasma renin levels because of the disruption of the
negative feedback of its production,7,41 which leads to a
decrease in the efficacy of RAS inhibition. This notion is
substantiated by the observation that trandolapril augments
the de novo expression of the renin gene in renal tubules after
injury (Figure 8). Renin is capable of promoting renal injury
not only by stimulating angiotensin II generation through its
enzymatic activity but also by eliciting cellular activities
through renin/prorenin receptor.8,9 Inhibition of renin
expression by paricalcitol would sustain and enhance the
efficacy of RAS inhibitors for renal protection. In this
context, combined treatment with paricalcitol and RAS
inhibitor would block angiotensin II generation and
concomitantly prevent renin increase, thereby leading to a
synergy in ameliorating renal fibrosis and inflammation.
Other potential mechanisms may also explain the synergy
between paricalcitol and trandolapril in renal protection. For
instance, although both paricalcitol and RAS inhibitor can
inhibit renal inflammation by suppressing NF-kB activation,
they might target at different events during NF-kB signaling.
Angiotensin II is known to activate NF-kB through multiple
pathways involving RhoA, IkB kinase, and ribosomal S6
kinase, leading to p65 NF-kB phosphorylation and activa-
tion.42,43 However, paricalcitol does not interfere with IkB
phosphorylation and degradation, p65 NF-kB activation and
its nuclear translocation, but it induces p65 sequestration by
activated VDR in the nuclei through physical interaction.25
Hence, a combination of paricalcitol and trandolapril could
result in an effective inhibition of NF-kB signaling at
multiple sites.
It should be noted that this study has some limitations.
One potential drawback is related to the UUO model itself, as
it is an extremely aggressive model of nephropathy
characterized by high inflammation and acute fibrosis,
features that are contrary to the slow progression of many
CKDs in a clinical setting. Furthermore, renal functional
assessment and long-term efficacy of combination therapy
are not examined, because of the acute nature and inherent
pitfalls of this fibrosis model. Nevertheless, our study may
offer significant insights into designing a rational therapeutic
regimen for the treatment of CKD. Given that both
paricalcitol and trandolapril are currently used in patients
for ameliorating secondary hyperparathyroidism and
hypertension, respectively, a regimen of combination therapy
on renal fibrosis and inflammation in humans warrants
further clinical investigations.
MATERIALS AND METHODS
Animals
Male CD-1 mice that weighed approximately 18–22 g were
purchased from Harlan Sprague Dawley (Indianapolis, IN, USA).
UUO was performed using an approved protocol by the Institu-
tional Animal Care and Use Committee at the University of
Pittsburgh, as described previously.44 Sham-operated mice were
used as normal controls. Five groups of animals were used: (1) sham
control; (2) UUO vehicle control; (3) UUO mice receiving 0.3 mg/kg
BW paricalcitol; (4) UUO mice receiving 3 mg/kg BW trandolapril;
and (5) UUO mice receiving 0.3 mg/kg BW paricalcitol and 3 mg/kg
BW trandolapril. Each group contained five mice (n¼ 5). At 1 day
before surgery (day -1), paricalcitol was administered by daily
subcutaneous injection, whereas trandolapril was administered
through oral treatment for 7 days. Both paricalcitol and trandolapril
were kindly provided by Abbott laboratories (Abbott Park, IL, USA).
UUO mice injected with the same volume of vehicle (ethanol) were
used as vehicle controls. Mice were killed 7 days after UUO, and
kidneys were removed for various analyses.
Reverse transcriptase-PCR
For determination of the steady-state levels of mRNA expression, a
semiquantitative reverse transcriptase-PCR was used. Total RNA was
prepared from kidney tissue by using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA), and was quantified by determination of
ultraviolet absorbance at 260 nm. The first strand of cDNA was
synthesized using 2 mg RNA in 20 ml of reaction buffer by reverse
transcription using AMV-RT (Promega, Madison, WI, USA) and
random primers, at 42 1C for 30 min. PCR was carried out using a
standard PCR kit on 1 ml aliquots of cDNA and HotStarTaq
polymerase (Qiagen, Valencia, CA, USA) using gene-specific primer
pairs. About 20 to 25 cycles at 94 1C for 1 min, 55 1C for 1 min, and
72 1C for 1 min for amplification in the linear range were used,
followed by a final extension step at 72 1C for 7 min. The PCR
products were size fractionated on agarose gels and detected by
ethidium bromide staining. After quantifying band intensities using
densitometry, the relative steady-state level of mRNA was calculated
after normalizing to b-actin. The sequences of primer sets for mouse
fibronectin, type I and type III collagen, Snail1, RANTES, TNF-a,
and b-actin were described previously.20,25,45 The sequences of
a-SMA and renin primer pairs were as follows: a-SMA, 50-ACCCTGC
TGCTTTGCCTAC (sense), and 50-GGTTCACGCCATTCTCCTG
(antisense); renin, 50-ATCTTTGACACGGGTTCAGC (sense), and
50-CACAGTGATTCCACCCACAG (antisense).
Western blot analysis
The preparation of whole-kidney tissue homogenates and western
blot analysis of protein expression were carried out using routine
procedures as described previously.20,46 The primary antibody
against a-SMA was obtained from Sigma (clone1A4) (St Louis,
MO, USA).
Immunofluorescence and immunohistochemical staining
Immunofluorescence and immunohistochemical staining of kidney
sections were performed by an established protocol.25,44 For
immunofluorescence staining, frozen sections of 4 mm thickness
were prepared and fixed in 4% paraformaldehyde in PBS for 30 min.
The slides were stained with specific antibodies against fibronectin
(cat.no. 610078; BD Transduction Laboratories, San Jose, CA, USA),
type I collagen (cat.no. 131001; Southern Biotech, Birmingham, AL,
USA), and type IV collagen (ab6586; Abcam, Cambridge, MA,
USA), using the Vector MOM immunodetection kit, according to
the protocol specified by the manufacturer (Vector Laboratories,
Burlingame, CA, USA). For immunohistochemical staining, paraf-
fin-embedded sections were stained with anti-CD3 (sc-20047) and
anti-renin (sc-27320) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-F4/80 (14-4801-82, eBioscience, San Diego, CA, USA),
and anti-vementin (v2258; Sigma) antibodies using the Vector
MOM immunodetection kit. Nonimmune normal control IgG was
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used to replace the primary antibody as negative control, and
no staining occurred. CD-3 and F4/80 staining were semi-quantified
by a computer-aided morphometric analysis (MetaMorph, Universal
Imaging, Downingtown, PA, USA). Briefly, a grid containing 117
(13 9) sampling points was superimposed on images of cortical
high-power field ( 400). The number of grid points overlying the
positive area (except tubular lumen and glomeruli) was counted and
expressed as a percentage of all sampling points (% of positive grid),
as described elsewhere.25,47 For each kidney, 10 randomly selected,
nonoverlapping fields were analyzed. Interstitial volume index was
determined as described previously.20
Quantitative determination of tissue hydroxyproline content
For quantitative measurement of collagen deposition in kidney, total
tissue collagen was estimated by biochemical analysis of hydroxypro-
line in the hydrolysates extracted from kidney samples. This assay is
based on the observation that essentially all the hydroxyprolines in
animal tissues are found in collagen. Briefly, kidney samples were
dried at 110 1C for 48 h, and then accurately weighed. Dry kidney
was hydrolyzed in sealed, oxygen-purged glass ampoules containing
2 ml of 6N HCl at 110 1C for 24 h. The hydroxyproline content in
hydrolysates was chemically quantified according to the techniques
previously described.45,48 The tissue hydroxyproline content was
expressed as mg/mg of dry kidney weight.
Statistical analyses
Statistical analysis of data was carried out using SigmaStat software
(Jandel Scientific, San Rafael, CA, USA). Comparison between
groups was made using one-way ANOVA, followed by Student–-
Newman–Kuels test. Po0.05 was considered to be significant.
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